Combination treatment for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new pill combined with immunotherapy for people with advanced non-small cell lung cancer that has not been treated or has stopped responding to previous immunotherapy. The goal is to see if the combination is safe and helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced non-small cell lung cancer (stage IIIB/IIIC or stage IV) that cannot be removed with surgery and is not suitable for chemotherapy and radiation.
- You have not had any treatment for your lung cancer, OR you had immunotherapy before and it worked for a while (at least 6 months) but then the cancer started growing again.
- You have at least one tumor that can be measured and a tumor that can be biopsied (a small sample taken) safely.
- You are in good enough health to carry out daily activities (ECOG score 0 or 1).
- Your blood counts and organ function (kidney, liver) are within acceptable ranges.
- You do not have certain genetic mutations in your tumor (EGFR, ALK, or ROS1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill (calderasib) combined with an immunotherapy drug (pembrolizumab) for people with a specific type of advanced non-small cell lung cancer. It aims to see if the combination can shrink tumors or slow their growth.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This study tests a new combination of drugs (SYHX2011, carboplatin, and an immunotherapy called enlonstobart) as the first treatment for advanced squamous lung cancer that is PD-L1 positive. The goal is to see if this combination helps shrink tumors and slow cancer growth.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a new treatment that combines a drug called SYS6010 with an immunotherapy (Enlonstobart) compared to the usual immunotherapy plus chemo for advanced lung cancer. The goal is to see if this combo works better and helps people with PD-L1 positive lung cancer live longer and feel better.
This trial tests a new combination of two drugs (Adibelimab and Famitinib) plus chemotherapy for people with advanced non-small cell lung cancer whose previous immunotherapy (PD-1 inhibitor) has stopped working. The goal is to see if this new combination can help control the cancer when the first treatment fails.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.